US industry concerned about FDA's data falsification rule

The US pharmaceutical and clinical research industry has expressed serious concerns about a new rule proposed by the Food and Drug Administration, which, if finalised, would require sponsors to report to the agency about any individual who has, or may have, engaged in falsification of data in studies involving human or animal subjects1,2.